View Filing Data

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2012	Feb. 15, 2013	Jun. 29, 2012
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	FY
Trading Symbol	PLX
Entity Registrant Name	Protalix BioTherapeutics, Inc.
Entity Central Index Key	0001006281
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Well Known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		93,497,809
Entity Public Float			$ 359

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
CURRENT ASSETS:
Cash and cash equivalents	$ 52,035	$ 27,001
Accounts receivable- Trade	1,410	1,374
Other assets	3,686	3,837
Inventories	4,039	279
Total current assets	61,170	32,491
FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT	1,247	1,043
PROPERTY AND EQUIPMENT, NET	16,310	18,271
Total assets	78,727	51,805
Accounts payable and accruals:
Trade	5,267	5,032
Other	11,051	7,540
Deferred revenues	9,437	6,121
Total current liabilities	25,755	18,693
LONG TERM LIABILITIES:
Deferred revenues	48,888	50,923
Liability in connection with collaboration operation	5,425	6,566
Liability for employee rights upon retirement	2,016	1,700
Total long term liabilities	56,329	59,189
Total liabilities	82,084	77,882
COMMITMENTS (Note 6)
CAPITAL DEFICIENCY:
Common Stock, $0.001 par value: Authorized - as of December 31, 2011 and 2012, 150,000,000 shares; issued and outstanding - as of December 31, 2011 and 2012, 85,630,157 and 93,489,809 shares, respectively	93	86
Additional paid-in capital	180,145	145,814
Accumulated deficit	(183,595)	(171,977)
Total capital deficiency	(3,357)	(26,077)
Total liabilities net of capital deficiency	$ 78,727	$ 51,805

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2012	Dec. 31, 2011
Common stock, par value per share	$ 0.001	$ 0.001
Common Stock, Authorized	150,000,000	150,000,000
Common Stock, issued	93,489,809	85,630,157
Common Stock, outstanding	93,489,809	85,630,157

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
REVENUES (see Note 9(c))	$ 34,870	$ 8,386	$ 6,642
COMPANY'S SHARE IN COLLABORATION AGREEMENT	(446)	(5,418)	4,602
COST OF REVENUES	(8,144)	(1,525)	(4,383)
GROSS PROFIT	26,280	1,443	6,861
RESEARCH AND DEVELOPMENT EXPENSES	(36,665)	(37,818)	(37,691)
Less - grants and reimbursements	7,976	6,775	7,740
RESEARCH AND DEVELOPMENT EXPENSES, NET	(28,689)	(31,043)	(29,951)
GENERAL AND ADMINISTRATIVE EXPENSES	(9,763)	(6,931)	(6,876)
OPERATING LOSS	(12,172)	(36,531)	(29,966)
FINANCIAL INCOME - NET	554	2	968
NET LOSS FOR THE YEAR	$ (11,618)	$ (36,529)	$ (28,998)
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:	$ (0.13)	$ (0.43)	$ (0.36)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE OF COMMON STOCK, BASIC AND DILUTED:	90,845,901	84,645,364	80,960,300

CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance, shares at Dec. 31, 2009		80,841,237
Balance at Dec. 31, 2009	$ 15,883	$ 81	$ 122,252	$ (106,450)
Share-based compensation	1,282		1,282
Exercise of options granted to employees and non-employees	510		510
Exercised		407,235
Net Loss	(28,998)			(28,998)
Balance at Dec. 31, 2010	(11,323)	$ 81	124,044	(135,448)
Balance, shares at Dec. 31, 2010		81,248,472
Common stock issued for cash (net of issuance costs) (in shares)		4,000,000
Common stock issued for cash (net of issuance costs)	20,590	$ 4	20,586
Share-based compensation	886		886
Exercise of options granted to employees and non-employees	299	$ 1	298
Exercised		381,685
Net Loss	(36,529)			(36,529)
Balance at Dec. 31, 2011	(26,077)	$ 86	145,814	(171,977)
Balance, shares at Dec. 31, 2011		85,630,157
Common stock issued for cash (net of issuance costs) (in shares)		5,175,000
Common stock issued for cash (net of issuance costs)	25,388	$ 5	25,383
Share-based compensation	4,612		4,612
Share-based compensation related to restricted stock award, net of forfeitures	3,139	$ 1	3,138
Share-based compensation related to restricted stock award, net of forfeitures (shares)		1,496,792
Exercise of options granted to employees and non-employees	1,199	$ 1	1,198
Exercised		1,187,860
Net Loss	(11,618)			(11,618)
Balance at Dec. 31, 2012	$ (3,357)	$ 93	$ 180,145	$ (183,595)
Balance, shares at Dec. 31, 2012		93,489,809

CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) [Abstract]
Common stock issued for cash, issuance costs	$ 1,780	$ 1,410
Restricted stock awards forfeited, share	3,208

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (11,618)	$ (36,529)	$ (28,998)
Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:
Share based compensation	7,751	886	1,282
Depreciation and write down of fixed assets	3,692	3,631	3,133
Financial expenses (income), net (mainly exchange differences)	(171)	350	(591)
Changes in accrued liability for employee rights upon retirement	276	155	377
Gain on amounts funded in respect of employee rights upon retirement	(36)	(14)	(26)
Loss on sale of fixed assets		8
Changes in operating assets and liabilities:
Increase (decrease) in deferred revenues (including non-current portion)	1,281	(3,005)	(4,563)
Decrease (increase) in accounts receivable and other assets	243	3,891	(6,860)
Decrease (increase) in inventories	(3,760)	910	(1,189)
Increase (decrease) in accounts payable and accruals (including long term)	2,977	6,147	(1,029)
Net cash provided by (used in) operating activities	635	(23,570)	(38,464)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(2,068)	(5,705)	(7,855)
Proceeds from sale of property and equipment		2
Investment in restricted deposit	(80)
Amounts funded in respect of employee rights upon retirement, net	(138)	(165)	(137)
Net cash used in investing activities	(2,286)	(5,868)	(7,992)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of shares, net of issuance cost	25,328	20,650
Exercise of options	1,230	277	501
Net cash provided by financing activities	26,558	20,927	501
EFFECT OF EXCHANGE RATE CHANGES ON CASH	127	(388)	589
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	25,034	(8,899)	(45,366)
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	27,001	35,900	81,266
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR	52,035	27,001	35,900
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
Purchase of property and equipment	1,136	1,473	2,720
Issuance cost not yet paid		60
Exercise of options granted to employees		$ 31	$ 9

SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2012

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES

General

Operation

Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx^® protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company's two subsidiaries are referred to collectively herein as the "Subsidiaries."

On May 1, 2012, the U.S. Food and Drug Administration ("FDA") approved taliglucerase alfa for injection, the Company's first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012 and recently in Uruguay. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by each of the FDA and the Israeli MOH.

Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO™ by Pfizer Inc. ("Pfizer"), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the "Pfizer Agreement"). The Company, through Protalix Ltd., markets ELELYSO in Israel.

Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA's approval of taliglucerase alfa in the United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel, where the Company retained exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.

In December 2012, Protalix Ltd. entered into a Clinical Development Agreement with Pfizer under which Protalix Ltd. will continue to manage, administer and sponsor current, ongoing clinical trials relating to taliglucerase alfa. According to the terms of the agreement, Protalix Ltd. was eligible to receive a payment of $8.3 million upon the achievement of certain near-term clinical development goals. The goals were achieved, and the payment made, in December 2012. The Company evaluated the terms of the agreement and the nature of the payment made by Pfizer and concluded that the amount received represents an upfront funding of the anticipated costs of the Company's ongoing clinical trials relating to taliglucerase alfa. Accordingly, the amount was deferred upon receipt and will be recognized as a reduction of research and development expenses over the ongoing clinical trial period.

The Company is cooperating with Pfizer to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed for Brazil and other countries. The European Commission (EC) issued a Commission Decision refusing the marketing authorization for taliglucerase alfa in the European Union. This decision is an endorsement of the EMA's Committee for Medicinal Products for Human Use (CHMP) June 2012 opinion recommending against the marketing authorization of taliglucerase alfa. While the CHMP gave a positive risk-benefit assessment for taliglucerase alfa, its recommendation was based solely on the orphan market exclusivity granted to VPRIV^®, Shire plc's Gaucher disease treatment. It was not based on the safety and efficacy profile of taliglucerase alfa.

In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.

Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States and Israel. In addition, patients are being treated globally through the Company's clinical trials and related studies, compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. Notwithstanding the EC's decision not to approve the market authorization of taliglucerase alfa in the EU, the Company, together with Pfizer, will continue to supply taliglucerase alfa as required by physicians under the ATU process for as long as it is authorized by the French regulatory authorities. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.

On August 10, 2010, Pfizer entered into a short-term supply agreement with the Ministry of Health of Brazil pursuant to which the Company and Pfizer have provided taliglucerase alfa to the Brazilian Ministry of Health for the treatment of Gaucher patients. During the remainder of 2010 and the first quarter of 2011, the Company and Pfizer completed the supply of products deliverable under the short-term supply agreement. During 2011, Pfizer recorded an allowance for sales returns in connection with the supply agreement because the Brazilian Ministry of Health requested that Pfizer consider the replacement of certain vials that might expire during 2012. During the third quarter of 2012 resupply for certain vials was completed. Revenue, net of allowance for sales returns, generated from the Brazilian Ministry of Health was recorded by Pfizer, and the Company recorded its share of such revenues in accordance with the terms and conditions of the Pfizer Agreement.

Liquidity and Financial Resources

In addition to the approval of taliglucerase alfa by the FDA and the Israeli MOH, successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. In accordance with the terms and conditions of the Pfizer Agreement, the Company received a $25.0 million milestone payment in connection with the FDA's approval of taliglucerase alfa in the United States. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all and the Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.

Obtaining marketing approval with respect to any product candidate is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these activities.

Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.

Basis of presentation

The Company's financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP").

Use of estimates in the preparation of financial statements

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.

Functional currency

The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. Most of the Company's revenues are derived in dollars. Most of the Company's expenses and capital expenditures are incurred in dollars, and the major source of the Company's financing has been provided in dollars.

Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i) for transactions - exchange rates at the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) - historical exchange rates. Currency transaction gains and losses are carried to financial income or expenses, as appropriate.

Cash equivalents

The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.

Inventories

Inventories are valued at the lower of cost or market. Cost of raw and packaging materials and purchased products is determined using the "moving average" basis.

Cost of finished products that are capitalized is determined as follows: the value of the raw and packaging materials component is determined primarily on a using the "moving average" basis; the value of the labor and overhead component is determined on an average basis over the production period.

Prior to the FDA's approval of taliglucerase alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and development expenses. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company capitalizes manufacturing costs associated with taliglucerase alfa.

Property and equipment

Property and equipment are stated at cost, net of accumulated depreciation and amortization.

The Company's assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:

	Years
Laboratory equipment		5
Furniture		10-15
Computer equipment		3

Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.

Impairment in value of long-lived assets:

The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.

Income taxes

Deferred income taxes

Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets.

The guidance prohibits the recognition of deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the above mentioned differences with respect to Protalix Ltd. were not reflected in the computation of deferred tax assets and liabilities.

Uncertainty in income taxes

Tax benefits recognized in the financial statements are those that the Company's management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company's management deems more likely than not to be sustained.

Revenue Recognition

The Company recognizes revenue when the earnings process is complete, which is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery of goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured.

Revenues from the license and supply agreement with Pfizer

The Company recognizes revenue from milestone payments received pursuant to the Pfizer Agreement in accordance with guidance regarding revenue recognition and accounting for revenue arrangements with multiple deliverables. As the arrangement with Pfizer requires the Company's continued involvement with respect to the proposed commercialization of taliglucerase alfa, the non-refundable, up-front license payment the Company received from Pfizer was deferred and recognized over the related performance period. The Company estimated the performance period of 14 years (commencing upon the date of the Company's receipt of the up-front license payment payable by Pfizer under the Pfizer Agreement) based on the date the last relevant patent expires. See Note 2. The Company adjusts the performance periods, if appropriate, based on the applicable facts and circumstances. Each milestone payment that is considered to be substantive for purposes of revenue recognition is recorded as revenue during the period during which the milestone is achieved.

Revenues from selling products to Pfizer

The Company recognizes revenues from products sold to Pfizer upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.

Company's share in the collaboration agreement

Under the terms and conditions of the Pfizer Agreement, the Company is entitled to 40% of the profits or loss from sales of taliglucerase alfa, and related expenses incurred, except with respect to sales in Israel, where the Company retained exclusive marketing rights. Since Pfizer bears most of the risks and rewards relating to the agreement, the Company's share in the profits and loss in the agreement is recognized on a net basis. The Company recognizes its share of net profit or loss from the Pfizer Agreement based on reports it receives from Pfizer summarizing the results of the collaborative activities under the agreement for the applicable period. Under the terms of the Pfizer Agreement, for its subsidiaries operating outside the United States, financial information is included based on the fiscal year ending November 30, while financial information for the U.S. entity is included based on the fiscal year ending December 31.

Research and development costs

Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the Office of the Chief Scientist of Israel's Ministry of Industry, Trade and Labor (the "OCS") are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiary will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred.

Reimbursements received from Pfizer are recognized when the reimbursements become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the reimbursements and there is reasonable assurance the reimbursements will be received. The reimbursements are deducted from the research and development expenses as the applicable costs are incurred.

In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date.

Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are consumed or the related services are performed.

Concentration of credit risks and trade receivable

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments.

The Company's trade receivable represents mainly amounts to be received from Pfizer, as the Company currently receives most of its revenues from Pfizer. The Company does not require Pfizer to post collateral with respect to the receivables. The Company performs periodic credit evaluations of Pfizer's financial condition and believes there is no significant risk with respect to Pfizer's payment of the receivables.

Share-based compensation

The Company accounts for employee's share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions.

The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach.

When stock options are granted as consideration for services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the stock options issued. Options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.

Net Loss per share

Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company's Common Stock, par value $0.001 per share (the "Common Stock") outstanding for each period.

Diluted LPS does not include 7,761,168, 7,469,088 and 7,280,469 shares of Common Stock underlying outstanding options and restricted shares of Common Stock for the fiscal years ended December 31, 2010, 2011 and 2012, respectively, because the effect would be anti-dilutive.

LICENSE AND SUPPLY AGREEMENT	12 Months Ended
LICENSE AND SUPPLY AGREEMENT	Dec. 31, 2012
LICENSE AND SUPPLY AGREEMENT [Abstract]
LICENSE AND SUPPLY AGREEMENT	NOTE 2 - LICENSE AND SUPPLY AGREEMENT On November 30, 2009, Protalix Ltd. and Pfizer entered into the Pfizer Agreement pursuant to which Pfizer was granted an exclusive, worldwide license to develop and commercialize taliglucerase alfa, except in Israel. Under the terms and conditions of the Pfizer Agreement, Protalix Ltd. retained the right to commercialize taliglucerase alfa in Israel. Under the Pfizer Agreement, Pfizer made an upfront payment to Protalix Ltd. of $60.0 million in connection with the execution of the agreement and shortly thereafter paid Protalix Ltd. an additional $5.0 million upon the Company's filing of a proposed pediatric investigation plan to the Pediatric Committee of the EMA. Protalix Ltd. received a $25.0 million milestone payment in connection with the approval of taliglucerase alfa by the FDA in May 2012. Protalix Ltd. is entitled to 40% of the results (profits or losses) earned on Pfizer's sales of taliglucerase alfa. Such result (profit or loss) will be calculated while, in addition to other adjustments, taking into account Protalix Ltd.'s cost of goods sold and Pfizer's commercial expenses, with certain expenses capped or borne solely by one party ("Collaboration Operation"). Of the losses incurred by the Collaboration Operation through December 31, 2011, 40% will be deducted from the cash payments to be paid to the Company as its share in the profits from future years, if any. This deduction will be limited to a certain percentage of any quarterly profit. As of December 31, 2012, the Company accrued a liability in respect of these losses equal to $8.5 million, out of which $5.4 million is classified as a long term liability, and the remainder is included in accounts payable and accruals-other. The Company has determined that the initial, non-refundable upfront license fee payment of $60.0 million together with the first $5.0 million payment will be recognized on a straight line basis as revenue over the estimated relationship period (approximately $4.6 million per year). The Company has estimated that the relationship period for its arrangement with Pfizer will be approximately 14 years (commencing upon the Company's receipt of the up-front license payment) based on the Company's last material patent relating to taliglucerase alfa to expire. The $25.0 million milestone payment received in connection with the FDA's approval of taliglucerase alfa in the United States was considered to be a substantive milestone for purposes of revenue recognition and, accordingly, was recorded as revenue during the period in which the milestone was achieved. The Company's deliverables under this collaboration include an exclusive license to taliglucerase alfa as an enzyme replacement therapy for the treatment of Gaucher disease, certain research and development services as required under the Pfizer Agreement for taliglucerase alfa and manufacturing of taliglucerase alfa. According to the terms and conditions of the Pfizer Agreement, the Company retained manufacturing rights and sells its products to Pfizer. In addition, Pfizer is required to reimburse the Company for certain costs it incurs in connection with certain development expenses for taliglucerase alfa. In connection with the payments received under the Pfizer Agreement, Protalix Ltd. is obligated to pay certain royalties. See Note 6a.

PROPERTY AND EQUIPMENT

12 Months Ended

Dec. 31, 2012

PROPERTY AND EQUIPMENT [Abstract]

PROPERTY AND EQUIPMENT

NOTE 3 - PROPERTY AND EQUIPMENT

Composition of property and equipment grouped by major classifications is as follows:

	December 31,
(U.S. dollars in thousands)	2011			2012
Laboratory equipment	$	13,079		$	14,502
Furniture and computer equipment		1,522			1,818
Leasehold improvements		13,705			14,447
Equipment under construction		1,113			329
	$	29,419		$	31,096

Less - accumulated depreciation and amortization		(11,148	)		(14,786	)
	$	18,271		$	16,310

Depreciation and amortization in respect of property and equipment totaled approximately $3.1 million, $3.6 million and $3.7 million for the years ended December 31, 2010, 2011 and 2012, respectively, out of which the Company recorded a total write down of approximately $43,000, $10,000 and $0, respectively.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

INVENTORIES

12 Months Ended

Dec. 31, 2012

INVENTORIES [Abstract]

INVENTORIES

NOTE 4 - INVENTORIES

Inventories at December 31, 2011 and 2012 consisted of the following:

	December 31,
(U.S. dollars in thousands)	2011		2012
Raw materials	$	279	$	2,118
Work in progress				192
Finished goods				1,729
Total inventory	$	279	$	4,039

During the year ended December 31, 2011 and 2012, the Company recorded approximately $363,000 and $684,000 respectively, for write-down of inventory under cost of revenues.

LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT	12 Months Ended
LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT	Dec. 31, 2012
LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT [Abstract]
LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT	NOTE 5 - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT The Israeli Subsidiary is required to make a severance payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest monthly salary - one month's salary for each year employed) is recorded on the Company's balance sheets under "Liability for employee rights upon retirement." The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis. The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Company's balance sheets under "Funds in respect of employee rights upon retirement." These policies are the Company's assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December 31, 2010, 2011 and 2012, the Company deposited approximately $174,000, $181,000 and $177,000, respectively, with insurance companies in connection with its severance payment obligations. In accordance with the current employment agreements with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee's rights upon retirement. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company's balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the "Contribution Plans"). The amounts of severance pay expenses were approximately $1.1 million, $816,000 and $1.0 million for the years ended December 31, 2010, 2011 and 2012, respectively, of which approximately $531,000 $641,000 and $670,000 in the years ended December 31, 2010, 2011 and 2012, respectively, were in respect of a Contribution Plan. Gain on amounts funded in respect of employee rights upon retirement totaled approximately $26,000, $14,000 and $36,000 for the years ended December 31, 2010, 2011 and 2012, respectively. The Company expects to contribute approximately $963,000 in the year ending December 31, 2013 to insurance companies in connection with its severance liabilities for its operations for that year, approximately $773,000 of which will be contributed to one or more Contribution Plans. During the five-year period following December 31, 2012, the Company expects to pay future benefits to 4 employees upon the employee's normal retirement age. The Company anticipates that the benefits payable will be immaterial.

- Definition

The entire disclosure for pension and other postretirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Implementation Guide (Q and A)
-Number FAS88
-Paragraph 63
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 106
-Paragraph 518
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-2
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 87
-Paragraph 264
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph q
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph h
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 8
-Subparagraph m
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 7, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS106-2
-Paragraph 20, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 30
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

COMMITMENTS

12 Months Ended

Dec. 31, 2012

COMMITMENTS [Abstract]

COMMITMENTS

NOTE 6 - COMMITMENTS

Royalty commitments

The Company is obligated to pay royalties to the OCS on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from the OCS. At the time the grants were received, successful development of the related projects was not assured.

In the case of failure of a project that was partly financed as described above, the Company is not obligated to pay any such royalties or repay funding received from the OCS.

Under the terms of the funding arrangements with the OCS, royalties of 3% to 6% are payable on the sale of products developed from projects funded by the OCS, which payments shall not exceed, in the aggregate, 100% of the amount of the grant received (dollar linked), plus, commencing upon January 1, 2001, interest at annual rate based on LIBOR. In addition, if the Company receives approval to manufacture products developed with government grants outside the State of Israel, it will be required to pay an increased total amount of royalties (possibly up to 300% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside the State of Israel, and, possibly, an increased royalty rate.

Royalty expenses to the OCS are included in the statement of operations as a component of the cost of revenues and were approximately $769,000, $158,000 and $1.5 million during the years ended December 31, 2010, 2011 and 2012, respectively.

At December 31, 2012, the maximum royalty amount payable by the Company under these funding arrangements is approximately $21.3 million (without interest, assuming 100% of the funds are payable).

The Company is a party to certain research and license agreements. Under the agreements, the Company is obligated to pay royalties at varying rates from its future revenues. The aggregate royalties payable under all of the agreements is equal to a varying range of percentages of net sales of licensed products. Royalty expenses under the agreements are included in the statement of operations as a component of the cost of revenues and were approximately $115,000, $19,000 and $674,000 during the years ended December 31, 2010, 2011 and 2012, respectively.

Under each agreement, the Company is also obligated to pay milestone, licensing and other payments to the counterparties of the agreement. The payments under the agreements are for varying amounts and are subject to varying conditions. If all of the contingencies with respect to milestone payments under the research and license agreements are met, the aggregate milestone payments payable would be approximately $1.0 million and would be payable, if at all, as the Company's projects progress over the course of a number of years. In addition, a milestone payment of approximately $100,000 was made in respect of the agreements during the year ended December 31, 2010. No milestone payments were made during 2011 and 2012.

None of the agreements has a fixed termination date. Subject to earlier termination for other reasons, each agreement terminates after a certain number of years following the first commercial sale of any licensed product under the agreement or after a certain number of years without the initiation of commercial sales of any product under the agreement.

Subcontracting Agreements

The Company has entered into sub-contracting agreements with several clinical providers and consultants in Israel, the United States and certain other countries in connection with its primary product development process and with expenditure of the company's manufacturing facilities. As of December 31, 2012, total commitments under said agreements were approximately $1.3 million.

Lease Agreements

The Company is a party to a number of lease agreements for its facilities, the latest of which expires in 2016. The Company has the option to extend certain of such agreements on three occasions for additional five-year periods, for a total of 15 additional years. Under the leases, the aggregate monthly rental payments are approximately $82,000. As of December 31, 2012, the Company provided bank guarantees of approximately $298,000, in the aggregate, to secure the fulfillment of its obligations under the lease agreements. The future minimum lease payments required in each of the next five years under the operating leases for such premises are approximately as follows: 2013 - $976,000, 2014 - $968,000, 2015 - $985,000 and 2016 - $823,000. Lease expenses totaled $891,000, $994,000 and $971,000 for the years ended December 31, 2010, 2011 and 2012, respectively.

Vehicle Lease and Maintenance Agreements

The Company entered into several three-year lease and maintenance agreements for vehicles which are regularly amended as new vehicles are leased. The current monthly lease fees aggregate approximately $49,000. The expected lease payments for the years ending December 31, 2013, 2014 and 2015 are approximately $526,000, $385,000 and $175,000, respectively.

Yissum Agreement

On August 8, 2007, the Company signed an agreement with the Yissum Research and Development Company, the technology transfer arm of the Hebrew University of Jerusalem, Israel ("Yissum"), and the Boyce Thompson Institute for Plant Research, at Cornell University, Ithaca, New York ("Boyce Thompson"), to develop a proprietary plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, including a biodefense program and organophosphate-based pesticide treatment. Pursuant to the agreement, the Company has received an exclusive worldwide right and license to certain technology, including patents and additional patent applications relating to AChE (the "Licensed Technology"), for all therapeutic and prophylactic indications. In consideration for the license, the Company is obligated to pay Yissum and Boyce Thompson, collectively, an annual, non-refundable initial maintenance fee of $20,000, commencing on the fourth anniversary of the execution of the agreement, which is subject to a 12% annual increase. In addition, the Company is required to make certain milestone payments equal to up to $700,000, in the aggregate, upon its achievement of clinical milestones and royalties from sales derived from any drugs developed by the Company with the Licensed Technology. The agreement does not terminate until either party to the agreement elect to terminate the agreement, subject to certain terms and conditions set forth therein.

SHARE CAPITAL

12 Months Ended

Dec. 31, 2012

SHARE CAPITAL [Abstract]

SHARE CAPITAL

NOTE 7 - SHARE CAPITAL

Rights of the Company's Common Stock

The Company's common stock is listed on the NYSE MKT and, since September 6, 2010, on the Tel Aviv Stock Exchange. Each share of Common Stock is entitled to one vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.

Stock based compensation

On December 14, 2006, the Board of Directors adopted the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan (the "Plan"). The Plan was amended on June 17, 2012 to increase the number of shares of common stock available under the plan from 9,741,655 shares to 11,341,655 shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections 102 and 102A of the Israeli Income Tax Ordinance. Each option grant is subject to the track chosen by the Company, either Section 102 or Section 102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company's accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section 3(i) of the Israeli Income Tax Ordinance.

As of December 31, 2012, 176,986 shares of Common Stock remain available for grant under the Plan.

For purposes of determining the fair value of the options and restricted stock granted to employees and non-employees, the Company's management uses the fair value of the Common Stock.

From January 1, 2010 through December 31, 2012, the Company granted options and shares of restricted stock to certain employees and non-employees as follows:

Options and restricted stock granted to employees:

Below is a table summarizing all of the options and restricted stock grants to employees for each of the three years in the three-year period ended December 31, 2012:

Year of grant		No. of options or restricted stock granted		Exercise price range		Vesting period	Fair value at grant (U.S. dollars in thousands)		Expiration period
	2010		1,016,000		$6.90	3 years commencing upon achievement of a certain milestone	$	5,673		10 years
	2010		428,000		$6.32-$9.66	4 years	$	2,147		10 years
	2012		400,000		n/a	3 years	$	2,288		n/a
	2012		1,100,000		n/a	4 years	$	6,292		n/a
			2,944,000

Set forth below are grants made by the Company to employees (including related parties) during the three-year period ended December 31, 2012 (such grants appear in the table above):

In February 2010, the Company's Board of Directors approved the grant of options to purchase 1,016,000 shares of Common Stock, in the aggregate, to the Company's Chief Executive Officer and certain officers and employees of the Company with an exercise price equal to $6.90 per share. The options vest quarterly over a three-year period commencing upon the FDA's approval of taliglucerase alfa. The Company treated the awards as performance-based awards and, given that the performance condition is outside the Company's control, concluded that the performance condition was not probable until the performance condition actually occurred. Upon the FDA's approval of taliglucerase alfa on May 1, 2012, the Company started recognizing share based compensation expenses related to such options. Share based compensation related to services performed from the date of grant of the respective options through the FDA approval date, were recognized on that date.

In February 2010, the Company's Board of Directors approved the grant of options to purchase 160,000 shares of Common Stock with an exercise price equal to $6.81 per share to a new executive officer of the Company. The options expire on the tenth anniversary of the date of grant, unless terminated earlier. The first 25% of the options vest on the first anniversary of the date of grant and the remaining 75% vest in 12 equal tranches on a quarterly basis for three years thereafter.

In September 2010, the Company's Board of Directors approved the grant of options to purchase 160,000 shares of Common Stock to a new executive officer of the Company with an exercise price equal to $7.55 per share and options to purchase 40,000 shares of Common Stock to a new employee of the Company with an exercise price equal to $6.32 per share. The options vest over a four-year period, with the first 25% vesting on the first anniversary of the applicable date of the grant and the remaining 75% vesting in equal tranches on a quarterly basis for a three-year period thereafter. The options expire on the tenth anniversary of the date of grant, unless terminated earlier.

In November 2010, the Company's Board of Directors approved the grant of options to purchase 68,000 shares of Common Stock to a new officer of the Company with an exercise price equal to $9.66 per share. The options vest over a four-year period, with the first 25% vesting on the first anniversary of the applicable date of the grant and the remaining 75% vesting in equal tranches on a quarterly basis for a three-year period thereafter. The options expire on the tenth anniversary of the date of grant, unless terminated earlier.

In September 2010, the Company's Board of Directors modified the terms of the options previously granted to an executive in 2001, by extending the life of the options until 2016. At the date of modification, all of the options were fully vested. The Company concluded that there was no incremental increase in the value of the awards and therefore no accounting charges need to be recorded in connection with the modifications.

On July 16, 2012, the Company's Board of Directors approved the grant of 1,500,000 shares of restricted Common Stock to its officers and certain other employees. Of such restricted stock, 1,100,000 of the shares were issued to the Company's named executive officers and vest in 16 equal, quarterly increments over a four-year period, commencing upon the date of grant, and are subject to a 24-month lock-up period, commencing upon the applicable vesting dates. Immediately and automatically in the event of a Change in Control, as such term is defined in the Plan, as amended, all of the shares of restricted Common Stock issued to the named executive officers shall vest, and the lock-up periods shall terminate, subject to certain exceptions. The remaining 400,000 shares of restricted Common Stock were issued to other employees of the Company and vest in 12 equal, quarterly increments over a three-year period, commencing upon the date of grant. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $8.6 million.

The fair value of options and restricted stock granted during the years ended December 31, 2010 and 2012 were $7.8 million and $8.6 million respectively. The fair value of each option granted in 2010 is estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted average assumptions:

	2010
Dividend yield		0	%
Expected volatility		75	%
Risk-free interest rate		3.23	%
Expected life - in years		8.8

The expected volatility is based on the historical volatility of the Common Stock and those of comparable companies. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the stock options granted in dollar terms. The Company's management uses the contractual term or its expectations, based on historical incidence of option exercises, as applicable (during 2010 - using the simplified method), of each option as its expected life. The pre-vesting forfeiture rate of approximately 6.1% is estimated based on pre-vesting forfeiture experience.

The fair value of the restricted stock is based on the Company's share price on the NYSE MKT on the grant date.

The total unrecognized compensation cost of employee stock options and restricted stock at December 31, 2012 is approximately $7.0 million (net of forfeiture rate). The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of 1.1 years.

The total cash received from employees as a result of employee stock option exercises for the years ended December 31, 2010, 2011 and 2012 was approximately $501,000, $277,000 and $1.2 million, respectively. The Company did not realize any tax benefit in connection with these exercises.

During 2012, the Company issued 861,593 shares of Common Stock in connection with the exercise of 861,593 options by certain employees of the Company. The Company received cash proceeds equal to approximately $1.2 million in connection with such exercises.

Options granted to consultants, directors, and other service providers:

As of December 31, 2012, the Company has recognized and recorded all compensation costs related to outstanding options for consultants, directors and other services providers.

No cash was received from consultants as a result of consultant stock option exercises for the years ended December 31, 2010, and 2011 and approximately $39,000 was received during the year ended December 31, 2012. The Company did not realize any tax benefits in connection with these exercises.

During 2012, the Company issued 326,267 shares of Common Stock in connection with the exercise of 326,267 options by consultants of the Company. The Company received cash proceeds equal to approximately $39,000 in connection with such exercise.

A summary of share option plans, and related information, under all of the Company's equity incentive plans for the years ended December 31, 2010, 2011 and 2012 are as follows:

Options granted to employees:

	Year ended December 31,
	2010				2011				2012
			Weighted				Weighted				Weighted
	Number		average		Number		average		Number		average
	of		exercise		of		exercise		of		exercise
	options		price		options		price		options		price
Outstanding at beginning of year		5,366,729	$	2.476		6,367,979	$	3.576		6,141,030	$	3.563
Changes during the year:
Granted		1,444,000		7.076
Forfeited and Expired		13,441		3.551		44,856		6.207		25,858		4.372
Exercised (*)		429,309		1.602		182,093		1.652		861,593		1.346
Outstanding at end of year		6,367,979	$	3.576		6,141,030	$	3.563		5,253,579	$	3.923
Exercisable at end of year		4,267,850	$	2.183		4,647,834	$	2.581		4,258,441	$	3.201

(*)

The total intrinsic value of options exercised during the years ended December 31, 2010, 2011 and 2012, was approximately $3.1 million, $1.3 million and $4.8 million, respectively.

Restricted stock granted to employees:

Year ended December 31, 2012
	Number of Restricted Shares
Outstanding at beginning of year
Changes during the year:
Granted		1,500,000
Forfeited		3,208
Outstanding at end of year		1,496,792
Exercisable at end of year		102,084

Options granted to consultants, directors, and other service providers:

	Year ended December 31,
	2010				2011				2012
			Weighted				Weighted				Weighted
	Number		average		Number		average		Number		average
	of		exercise		of		exercise		of		exercise
	options		price		options		price		options		price
Outstanding at beginning of year		1,438,692	$	4.697		1,438,692	$	4.697		1,238,692	$	5.385
Changes during the year- Exercised (*)						200,000		0.001		326,267		0.12
Outstanding at end of year		1,438,692	$	4.697		1,238,692	$	5.385		912,425	$	7.259
Exercisable at end of year		1,421,734	$	4.653		1,235,567	$	5.385		912,425	$	7.259

(*)

The total intrinsic value of options exercised during the years ended December 31, 2010, 2011 and 2012, was approximately $0, $1.9 million and $2.3 million, respectively.

The following tables summarize information concerning outstanding and exercisable options and restricted stock as of December 31, 2012:

December 31, 2012
Options and restricted stock outstanding						Options exercisable and restricted stock vested
Exercise prices		Number of Options and restricted stock outstanding at end of year		Weighted average remaining contractual life		Number of options exercisable and restricted stock vested at end of year		Weighted average remaining contractual life
	n/a (Restricted Stock)		1,496,792		n/a		102,084		n/a
$	0.001		719,207		2.54		719,207		2.54
$	0.120		447,850		1.05		447,850		1.05
$	0.399		23,087		1.92		23,087		1.92
$	0.972		996,353		3.44		996,353		3.44
$	2.350		40,000		5.82		40,000		5.82
$	2.650		402,882		6.15		396,744		6.15
$	3.020		50,000		5.10		50,000		5.10
$	5.000		1,708,000		5.10		1,708,000		5.10
$	6.810		160,000		7.10		110,000		7.10
$	6.900		1,003,083		7.15		168,083		7.15
$	7.550		160,000		7.66		90,000		7.66
$	9.660		68,000		7.83		34,000		7.83
$	16.700		387,542		3.99		387,542		3.99
			7,662,796				5,272,950

The aggregate intrinsic value of the total outstanding and of total vested and exercisable options and restricted stock as of December 31, 2012 is approximately $19.7 million and $12.4 million, respectively.

The following table illustrates the effect of share-based compensation on the statement of operations:

	Year ended December 31,
(U.S. dollars in thousands)	2010		2011		2012
Cost of revenues					$	220
Research and development expenses	$	630	$	422		4,756
General and administrative expenses		652		464		2,775
	$	1,282	$	886	$	7,751

Public Offerings

On March 23, 2011, the Company issued and sold 4,000,000 shares of Common Stock in an underwritten public offering at a price to the public of $5.50 per share. The net proceeds to the Company were approximately $20.6 million (net of underwriting commissions and issuance costs of $1.4 million)

On February 22, 2012, the Company issued and sold 5,175,000 shares of Common Stock in an underwritten public offering at a price to the public of $5.25 per share. The net proceeds to the Company were approximately $25.4 million (net of underwriting commissions and issuance costs of $1.8 million).

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

TAXES ON INCOME

12 Months Ended

Dec. 31, 2012

TAXES ON INCOME [Abstract]

TAXES ON INCOME

NOTE 8 - TAXES ON INCOME

The Company

Protalix BioTherapeutics, Inc. is taxed according to U.S. tax laws. The Company's income is, or will be, taxed in the United States at the rate of up to 39%.

Protalix Ltd.

The Israeli Subsidiary is taxed according to Israeli tax laws:

Measurement of results for tax purposes

Since 2008, the Company has measured the results of the Israeli Subsidiary for tax purposes in nominal terms in NIS. Pursuant to the Israel Income Tax Law (Adjustments for Inflation), 1985 (the "Adjustments Law"), the Subsidiary's results for tax purposes have been measured through 2007 on a real basis, based on changes in the Israel consumer price index.

Tax rates

The income of the Israeli Subsidiary, other than income from "Approved Enterprises," is taxed in Israel at the regular rate. See 3 below. According to the provisions of the Law for Amending the Israel Income Tax Ordinance, 2005, corporate tax rates will be gradually lowered, resulting in a corporate tax rate for 2009 and thereafter: 2009 - 26% and for 2010 and thereafter - 25%.

On July 14, 2009, the Israel Economic Efficiency Law (Legislation Amendments for Applying the Economic Plan for 2009 and 2010), 2009, became effective, stipulating, among other things, an additional gradual decrease in tax rates in 2011 and thereafter, as follows: 2011 - 24%, 2012 - 23%, 2013 - 22%, 2014 - 21%, 2015 - 20% and 2016 and thereafter - 18%.

On December 5, 2011, the "Tax Burden Distribution Law" (hereinafter - the 2011 amendment) was officially published, discontinuing a previously approved gradual decrease in corporate tax provided in the 2009 amendment, and setting the corporate tax rate in Israel for 2012 and thereafter to 25%.

Capital gain is subject to capital gain tax according to corporate tax rate in the year of selling the assets.

The Law for the Encouragement of Capital Investments, 1959 (the "Encouragement of Capital Investments Law")

Under the Encouragement of Capital Investments Law, including Amendment No. 60 to the Encouragement of Capital Investments Law as published in April 2005, by virtue of the "Approved Enterprise" or "Benefited Enterprise" status the Israeli Subsidiary is entitled to various tax benefits as follows:

Reduced tax rates

Income derived from the Approved Enterprise during a 10-year period commencing upon the year in which the enterprise first realizes taxable income is tax exempt, provided that the maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.

The Israeli Subsidiary has an "Approved Enterprise" plan since 2004 and "Benefited Enterprise" plan since 2009. The period of benefits in respect of the main enterprise of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited Enterprise expires in 2021.

If the Israeli Subsidiary subsequently pays a dividend out of income derived from the "Approved Enterprise" or "Benefited Enterprise" during the tax exemption period, it will be subject to a tax on the amount distributed, including any company tax on these amounts, at the rate which would have been applicable had such income not been exempted.

In addition to the corporate taxes in Israel, the Company might be subject to a withholding tax on the U.S. revenue source portion of the payments made to the Company for its share of Pfizer's net profits under the Pfizer Agreement. The withholding tax rate is currently 15%.

Accelerated depreciation

The Israeli Subsidiary is entitled to claim accelerated depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery and equipment used by the Approved Enterprise and the Benefited Enterprise.

Conditions for entitlement to the benefits

The Israeli Subsidiary's entitlement to the benefits described above is subject to its fulfilling the conditions stipulated by the law, rules and regulations published thereunder, and the instruments of approval for the specific investment in an approved enterprise. If there is any failure by the Israeli Subsidiary to comply with these conditions, the benefits may be cancelled and the Subsidiary may be required to refund the amount of the benefits, in whole or in part, with interest. The Israeli Subsidiary received a final implementation approval with respect to its "Approved Enterprise" from the Investment Center.

Amendment of the Law for the Encouragement of Capital Investments, 1959

The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the years 2011-2012, which was passed by the Israeli Knesset on December 29, 2010 (the "Capital Investments Law Amendment").

The Capital Investments Law Amendment sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law.

The benefits granted to the Benefited Enterprises will be unlimited in time, unlike the benefits granted to special Benefited enterprises, which will be limited for a 10-year period. The benefits shall be granted to companies that will qualify under criteria set in the law; for the most part, those criteria are similar to the criteria that were set in the Encouragement of Capital Investments Law prior to its amendment.

Under the transitional provisions of the Encouragement of Capital Investments Law, the Company is entitled to take advantage of the tax benefits available under the Encouragement of Capital Investments Law prior to its amendment until the end of the benefits period, as defined in the Encouragement of Capital Investments Law. The Company will be allowed to set the "year of election" no later than tax year 2012, provided that the minimum qualifying investment was made not later than the end of 2010. On each year during the benefits period, the Company will be able to elect that the Capital Investments Amendment apply to the Company, thereby making the tax rates described above available to the Company. An election to have the Capital Investments Amendment apply is irrecoverable. The Company elected not to have the Capital Investments Amendment apply to the Company.

The Law for the Encouragement of Industry (Taxation), 1969:

The Israeli Subsidiary is an "industrial company," as defined under the Law for the Encouragement of Industry (Taxation), 1969 (the "Law for the Encouragement of Industry"). As such, the Israeli Subsidiary is entitled to claim depreciation at increased rates for equipment used in industrial activity, as stipulated by regulations published under Law for the Encouragement of Industry, and has done so.

Under the provisions of the Income Tax Regulations "Accelerated Depreciation in respect of Equipment acquired during the Defined Period" (Temporary Orders), industrial companies whose operations are mostly "eligible operations" are entitled to claim accelerated depreciation at a rate of 50% on machinery and equipment acquired from June 1, 2008 to May 31, 2009.

Tax losses carried forward to future years

As of December 31, 2012, the Company had aggregate net operating loss (NOL) carry-forwards equal to approximately $72.5 million that are available to reduce future taxable income as follows:

The Company

The NOL carry-forward of the Company equal to approximately $13.8 million may be restricted under Section 382 of the Internal Revenue Code ("IRC"). IRC Section 382 applies whenever a corporation with NOL experiences an ownership change. As a result of IRC Section 382, the taxable income for any post change year that may be offset by a pre-change NOL may not exceed the general IRC Section 382 limitation, which is the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate.

Protalix Ltd.

At December 31, 2012, the Israeli Subsidiary had approximately $58.7 million of NOL carry-forwards that are available to reduce future taxable income with no limited period of use.

Deferred income taxes:

The components of the Company's net deferred tax assets at December 31, 2011 and 2012 were as follows:

	December 31,
(U.S. dollars in thousands)	2011			2012
In respect of:
Research and development expenses	$	4,119			6,003
Property and equipment		(149	)		(647	)
Provision for vacation		305			363
Severance pay obligation		164			192
Deferred revenues		4,746			10,449
Net operating loss carry forwards		4,579			15,176
Valuation allowance		(13,764	)		(31,536	)
		-			-

Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse. The Company used tax rates of 39%, 25% and 0%.

Reconciliation of the theoretical tax expense to actual tax expense

The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).

Tax assessments

In accordance with the Income Tax Ordinance, as of December 31, 2012, all of Protalix Ltd.'s tax assessments through tax year 2008 are considered final.

A summary of open tax years by major jurisdiction is presented below:

Jurisdiction:			Years:
Israel			2009-2012
United States (*)			2009-2012
Netherlands			2009-2012

(*) Includes federal, state and local (or similar provincial jurisdictions) tax positions.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

+ Details

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION

12 Months Ended

Dec. 31, 2012

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION

NOTE 9 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION

Balance sheets:

	December 31,
(U.S. dollars in thousands)	2011		2012
a. Other assets:
Deferred costs*	$	1,558	$	89
Institutions		375		542
State of Israel (see Note 6a)		1,296		2,400
Restricted deposit		208		298
Prepaid expenses		235		251
Sundry		165		106
	$	3,837	$	3,686

* Manufacturing costs of inventory, paid by Pfizer, but not delivered.

(U.S. dollars in thousands)

Accounts payable and accruals - other:

Payroll and related expenses	$	1,108	$	1,748
Provision for vacation		1,221		1,453
Accrued expenses		2,327		2,032
Royalties payable		89		1,560
Liability in connection with collaboration operation- current portion		1,322		3,122
Property and equipment suppliers		1,473		1,136
	$	7,540	$	11,051

Statements of operations:

	Year ended December 31,
	2010		2011		2012
(U.S. dollars in thousands)
c. Revenues:
Deferred revenues from the license and supply agreement with Pfizer	$	4,563	$	4,563	$	4,563
Milestone payment (see note 2)						25,000
Revenues from selling products		2,079		3,823		5,307
	$	6,642	$	8,386	$	34,870

RELATED PARTY TRANSACTIONS

12 Months Ended

Dec. 31, 2012

RELATED PARTY TRANSACTIONS

NOTE 10 - RELATED PARTY TRANSACTIONS

	Year ended December 31,
(U.S. dollars in thousands)	2010		2011		2012
a. Management and consulting fees to the Chairman of the Board	$	6		-		-
b. Compensation to the non-executive directors (except the Chairman of the Board in 2010, and includes the interim Chairman of the Board in 2011 and 2012)	$	215	$	215	$	375

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph b
-Article 3A

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph k
-Article 4

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2012

SUBSEQUENT EVENTS [Abstract]

SUBSEQUENT EVENTS

NOTE 11 - SUBSEQUENT EVENTS

During January and February 2013, the Company issued a total of 8,000 shares of Common Stock in connection with the exercise of options to purchase 8,000 shares of Common Stock by certain employees of the Company. The Company received aggregate cash proceeds equal to approximately $19,000 in connection with the exercise of such options.

SIGNIFICANT ACCOUNTING POLICIES (Policy)

12 Months Ended

Dec. 31, 2012

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Basis of presentation

The Company's financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP").

Use of estimates in the preparation of financial statements

Functional currency

Cash equivalents

Inventories

Inventories are valued at the lower of cost or market. Cost of raw and packaging materials and purchased products is determined using the "moving average" basis.

Property and equipment

Property and equipment are stated at cost, net of accumulated depreciation and amortization.

The Company's assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:

	Years
Laboratory equipment		5
Furniture		10-15
Computer equipment		3

Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.

Impairment in value of long-lived assets

Impairment in value of long-lived assets:

Income taxes

Deferred income taxes

Uncertainty in income taxes

Revenue Recognition

Revenues from the license and supply agreement with Pfizer

Revenues from selling products to Pfizer

The Company recognizes revenues from products sold to Pfizer upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.

Company's share in the collaboration agreement

Research and development costs

Concentration of credit risks and trade receivable

Share-based compensation

Net Loss per share

SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2012

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Schedule of Useful Life

	Years
Laboratory equipment		5
Furniture		10-15
Computer equipment		3

PROPERTY AND EQUIPMENT (Tables)

12 Months Ended

Dec. 31, 2012

PROPERTY AND EQUIPMENT [Abstract]

Schedule of Property and Equipment

	December 31,
(U.S. dollars in thousands)	2011			2012
Laboratory equipment	$	13,079		$	14,502
Furniture and computer equipment		1,522			1,818
Leasehold improvements		13,705			14,447
Equipment under construction		1,113			329
	$	29,419		$	31,096

Less - accumulated depreciation and amortization		(11,148	)		(14,786	)
	$	18,271		$	16,310

INVENTORIES (Tables)

12 Months Ended

Dec. 31, 2012

INVENTORIES [Abstract]

Schedule of Inventory

	December 31,
(U.S. dollars in thousands)	2011		2012
Raw materials	$	279	$	2,118
Work in progress				192
Finished goods				1,729
Total inventory	$	279	$	4,039

SHARE CAPITAL (Tables)

12 Months Ended

Dec. 31, 2012

SHARE CAPITAL [Abstract]

Schedule of Options and Restricted Stocks Granted

Year of grant		No. of options or restricted stock granted		Exercise price range		Vesting period	Fair value at grant (U.S. dollars in thousands)		Expiration period
	2010		1,016,000		$6.90	3 years commencing upon achievement of a certain milestone	$	5,673		10 years
	2010		428,000		$6.32-$9.66	4 years	$	2,147		10 years
	2012		400,000		n/a	3 years	$	2,288		n/a
	2012		1,100,000		n/a	4 years	$	6,292		n/a
			2,944,000

Schedule of Assumptions Used to Estimate Fair Value of Stock Option Award using Black-Scholes Valuation Model

	2010
Dividend yield		0	%
Expected volatility		75	%
Risk-free interest rate		3.23	%
Expected life - in years		8.8

Summary of Stock Option Activity - Options Granted to Employees

	Year ended December 31,
	2010				2011				2012
			Weighted				Weighted				Weighted
	Number		average		Number		average		Number		average
	of		exercise		of		exercise		of		exercise
	options		price		options		price		options		price
Outstanding at beginning of year		5,366,729	$	2.476		6,367,979	$	3.576		6,141,030	$	3.563
Changes during the year:
Granted		1,444,000		7.076
Forfeited and Expired		13,441		3.551		44,856		6.207		25,858		4.372
Exercised (*)		429,309		1.602		182,093		1.652		861,593		1.346
Outstanding at end of year		6,367,979	$	3.576		6,141,030	$	3.563		5,253,579	$	3.923
Exercisable at end of year		4,267,850	$	2.183		4,647,834	$	2.581		4,258,441	$	3.201

Summary of Restricted Stock Activity - Options Granted to Employees

Year ended December 31, 2012
	Number of Restricted Shares
Outstanding at beginning of year
Changes during the year:
Granted		1,500,000
Forfeited		3,208
Outstanding at end of year		1,496,792
Exercisable at end of year		102,084

Schedule of Options Granted to Service Providers

	Year ended December 31,
	2010				2011				2012
			Weighted				Weighted				Weighted
	Number		average		Number		average		Number		average
	of		exercise		of		exercise		of		exercise
	options		price		options		price		options		price
Outstanding at beginning of year		1,438,692	$	4.697		1,438,692	$	4.697		1,238,692	$	5.385
Changes during the year- Exercised (*)						200,000		0.001		326,267		0.12
Outstanding at end of year		1,438,692	$	4.697		1,238,692	$	5.385		912,425	$	7.259
Exercisable at end of year		1,421,734	$	4.653		1,235,567	$	5.385		912,425	$	7.259

Schedule of Information about Share Options Outstanding

December 31, 2012
Options and restricted stock outstanding						Options exercisable and restricted stock vested
Exercise prices		Number of Options and restricted stock outstanding at end of year		Weighted average remaining contractual life		Number of options exercisable and restricted stock vested at end of year		Weighted average remaining contractual life
	n/a (Restricted Stock)		1,496,792		n/a		102,084		n/a
$	0.001		719,207		2.54		719,207		2.54
$	0.120		447,850		1.05		447,850		1.05
$	0.399		23,087		1.92		23,087		1.92
$	0.972		996,353		3.44		996,353		3.44
$	2.350		40,000		5.82		40,000		5.82
$	2.650		402,882		6.15		396,744		6.15
$	3.020		50,000		5.10		50,000		5.10
$	5.000		1,708,000		5.10		1,708,000		5.10
$	6.810		160,000		7.10		110,000		7.10
$	6.900		1,003,083		7.15		168,083		7.15
$	7.550		160,000		7.66		90,000		7.66
$	9.660		68,000		7.83		34,000		7.83
$	16.700		387,542		3.99		387,542		3.99
			7,662,796				5,272,950

Schedule of Stock-Based Compensation Expense in Statement of Operations

	Year ended December 31,
(U.S. dollars in thousands)	2010		2011		2012
Cost of revenues					$	220
Research and development expenses	$	630	$	422		4,756
General and administrative expenses		652		464		2,775
	$	1,282	$	886	$	7,751

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details

TAXES ON INCOME (Tables)

12 Months Ended

Dec. 31, 2012

TAXES ON INCOME [Abstract]

Schedule of Deferred Tax Assets

	December 31,
(U.S. dollars in thousands)	2011			2012
In respect of:
Research and development expenses	$	4,119			6,003
Property and equipment		(149	)		(647	)
Provision for vacation		305			363
Severance pay obligation		164			192
Deferred revenues		4,746			10,449
Net operating loss carry forwards		4,579			15,176
Valuation allowance		(13,764	)		(31,536	)
		-			-

Schedule of Open Tax Years

Jurisdiction:			Years:
Israel			2009-2012
United States (*)			2009-2012
Netherlands			2009-2012

(*) Includes federal, state and local (or similar provincial jurisdictions) tax positions.

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)

12 Months Ended

Dec. 31, 2012

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]

Supplemental Information, Balance Sheets

	December 31,
(U.S. dollars in thousands)	2011		2012
a. Other assets:
Deferred costs*	$	1,558	$	89
Institutions		375		542
State of Israel (see Note 6a)		1,296		2,400
Restricted deposit		208		298
Prepaid expenses		235		251
Sundry		165		106
	$	3,837	$	3,686

* Manufacturing costs of inventory, paid by Pfizer, but not delivered.

(U.S. dollars in thousands)

Accounts payable and accruals - other:

Payroll and related expenses	$	1,108	$	1,748
Provision for vacation		1,221		1,453
Accrued expenses		2,327		2,032
Royalties payable		89		1,560
Liability in connection with collaboration operation- current portion		1,322		3,122
Property and equipment suppliers		1,473		1,136
	$	7,540	$	11,051

Supplemental Information, Income Statement

	Year ended December 31,
	2010		2011		2012
(U.S. dollars in thousands)
c. Revenues:
Deferred revenues from the license and supply agreement with Pfizer	$	4,563	$	4,563	$	4,563
Milestone payment (see note 2)						25,000
Revenues from selling products		2,079		3,823		5,307
	$	6,642	$	8,386	$	34,870

RELATED PARTY TRANSACTIONS (Tables)

12 Months Ended

Dec. 31, 2012

Schedule of Related Party Transactions

	Year ended December 31,
(U.S. dollars in thousands)	2010		2011		2012
a. Management and consulting fees to the Chairman of the Board	$	6		-		-
b. Compensation to the non-executive directors (except the Chairman of the Board in 2010, and includes the interim Chairman of the Board in 2011 and 2012)	$	215	$	215	$	375

SIGNIFICANT ACCOUNTING POLICIES (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2011 $ / shares shares	Dec. 31, 2010 shares
Significant Accounting Policies [Line Items]
Number of Subsidiaries	2
Pfizer Agreement, upfront payment received	$ 60,000
Common stock, par value per share \| $ / shares	$ 0.001	$ 0.001
Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive \| shares	7,761,168	7,469,088	7,280,469
Protalix Bio Therapeutics Incorporation [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, future revenues and expense sharing percentage	40.00%
Pfizer Incorporation [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, future revenues and expense sharing percentage	60.00%
Upon Filing of Pediatric Investigation Plan to EMA [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, upfront payment received	$ 5,000
Upon each FDA and European Medicine Agency approval [Member]
Significant Accounting Policies [Line Items]
Milestone payment triggered	25,000
Upon FDAApproval [Member]
Significant Accounting Policies [Line Items]
Milestone payment triggered	25,000
Upon Near Term Clinical Development Milestones [Member]
Significant Accounting Policies [Line Items]
Milestone payment triggered	$ 8,300

SIGNIFICANT ACCOUNTING POLICIES (Useful Lives of Property and Equipment) (Details)	12 Months Ended
	Dec. 31, 2012
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years
Furniture [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	10 years
Furniture [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	15 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	3 years

LICENSE AND SUPPLY AGREEMENT (Details) $ in Thousands	12 Months Ended
LICENSE AND SUPPLY AGREEMENT (Details) $ in Thousands	Dec. 31, 2012 USD ($)
Significant Accounting Policies [Line Items]
Pfizer Agreement, upfront payment received	$ 60,000
Revenue recognized over designated period of relationship	$ 4,600
Revenue recognition period	14 years
Protalix Bio Therapeutics Incorporation [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, future revenues and expense sharing percentage	40.00%
Collaboration Operation [Member]
Significant Accounting Policies [Line Items]
Accrued liabilities accrued related to the Collaboration Operation	$ 8,500
Accrued long term liabilities	$ 5,400
Pfizer Incorporation [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, future revenues and expense sharing percentage	60.00%
Upon Filing of Pediatric Investigation Plan to EMA [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, upfront payment received	$ 5,000
Upon each FDA and European Medicine Agency approval [Member]
Significant Accounting Policies [Line Items]
Milestone payment triggered	25,000
Upon FDAApproval [Member]
Significant Accounting Policies [Line Items]
Milestone payment triggered	25,000
Upon Near Term Clinical Development Milestones [Member]
Significant Accounting Policies [Line Items]
Milestone payment triggered	$ 8,300

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	12 Months Ended
PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 31,096	$ 29,419
Less - accumulated depreciation and amortization	(14,786)	(11,148)
Property, Plant and Equipment, Net, Total	16,310	18,271
Depreciation and write down of fixed assets	3,692	3,631	$ 3,133
Impairment charges	0	10	$ 43
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	14,502	13,079
Furniture And Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,818	1,522
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	14,447	13,705
Equipment Under Construction [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 329	$ 1,113

INVENTORIES (Details) - USD ($) $ in Thousands	12 Months Ended
INVENTORIES (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
INVENTORIES [Abstract]
Raw materials	$ 2,118	$ 279
Work in process	192
Finished goods	1,729
Total inventory	4,039	279
Inventory write-down	$ 684	$ 363

- Definition

Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.

+ References + Details

LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT [Abstract]
Employee severance obligation payments	$ 177	$ 181	$ 174
Severance expense	1,000	816	1,100
Contributions	670	641	531
Net (gain) or loss for the period	36	$ 14	$ 26
Expected severance liabilities payments for fiscal year end 2013	963
Expected contribution to one or more Contribution Plans	$ 773

- Definition

The charge against earnings in the period for known and estimated costs of termination benefits provided to current employees that are involuntarily terminated under a benefit arrangement associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination or a discontinued operation as defined by generally accepted accounting principles and costs associated with one-time termination benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=6394695&loc=d3e140904-122747

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(10)
-URI http://asc.fasb.org/extlink&oid=21915506&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.P.3)
-URI http://asc.fasb.org/extlink&oid=6394695&loc=d3e140864-122747

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5-8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
-Paragraph 8-13, 20
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS146-1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 112
-Paragraph 7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

COMMITMENTS (Details) - USD ($) $ in Thousands	12 Months Ended
COMMITMENTS (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Commitments And Contingencies [Line Items]
Subcontracting commitment amount	$ 1,300
OCS [Member]
Commitments And Contingencies [Line Items]
Royalty expense included in cost of revenue	1,500	$ 158	$ 769
Research And License Agreements [Member]
Commitments And Contingencies [Line Items]
Royalty expense included in cost of revenue	674	19	115
Probable Aggregate Milestone Payment [Member]
Commitments And Contingencies [Line Items]
Royalty expense included in cost of revenue	1,000
Milestone Payments [Member]
Commitments And Contingencies [Line Items]
Royalty expense included in cost of revenue			100
Consideration for license	700
Lease Agreements [Member]
Commitments And Contingencies [Line Items]
Monthly rent/lease expense	82
Cash deposited as bank guarantee	298
Lease/rent expense	971	$ 994	$ 891
Future minimum lease payments, 2013	976
Future minimum lease payments, 2014	968
Future minimum lease payments, 2015	985
Future minimum lease payments, 2016	823
Vehicle Lease And Maintenance Agreements [Member]
Commitments And Contingencies [Line Items]
Monthly rent/lease expense	49
Future minimum lease payments, 2013	526
Future minimum lease payments, 2014	385
Future minimum lease payments, 2015	175
Yissum Agreement [Member]
Commitments And Contingencies [Line Items]
Agreement maintenance fee	$ 20
Percentage amount the aggregate amount of royalties that should not exceed grant received	12.00%
Minimum [Member] \| OCS [Member]
Commitments And Contingencies [Line Items]
Royalties based on sale of products developed from funded projects, percentage	3.00%
Maximum [Member] \| OCS [Member]
Commitments And Contingencies [Line Items]
Royalties based on sale of products developed from funded projects, percentage	6.00%
Percentage amount the aggregate amount of royalties that should not exceed grant received	100.00%
Accrued royalties	$ 21,300
Maximum [Member] \| Products Manufactured Outside Of Israel [Member]
Commitments And Contingencies [Line Items]
Royalties based on sale of products developed from funded projects, percentage	300.00%

SHARE CAPITAL (Narrative) (Details) $ / shares in Units, $ in Thousands		1 Months Ended					12 Months Ended
	Jul. 16, 2012 USD ($) shares	Feb. 29, 2012 USD ($)	Mar. 23, 2011 USD ($) $ / shares shares	Nov. 30, 2010 $ / shares shares	Sep. 30, 2010 $ / shares shares	Feb. 28, 2010 $ / shares shares	Dec. 31, 2012 USD ($) shares	Jun. 17, 2012 shares	Jun. 16, 2012 shares	Feb. 22, 2012 $ / shares shares	Dec. 31, 2011 shares	Dec. 31, 2010 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Underwritten public offering, common stock issued and sold			4,000,000				93,489,809			5,175,000	85,630,157
Underwritten public offering, common stock price per share \| $ / shares			$ 5.5							$ 5.25
Underwritten public offering, net proceeds from issuance \| $		$ 25,400	$ 20,600
Underwritten public offering, commissions and issuance costs \| $		$ 1,800	$ 1,400
Shares of common stock approved for grant								11,341,655	9,741,655
Common stock available for issuance							176,986
Fair value of common stock at grant date \| $							$ 8,600					$ 7,800
Officers And Certain Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock approved for grant						1,016,000
Exercise price \| $ / shares						$ 6.9
Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock approved for grant				68,000	160,000	160,000
Exercise price \| $ / shares				$ 9.66	$ 7.55	$ 6.81
Vesting period				4 years	4 years	4 years
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock approved for grant					40,000
Common stock shares granted							2,944,000
Vesting period					4 years
Restricted Stock [Member] \| Officers And Certain Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock approved for grant	1,500,000
Shares of common stock issued, lock up period	24 months
Number of installments for vesting of stock	16
Restricted Stock [Member] \| Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Underwritten public offering, common stock issued and sold	400,000
Number of installments for vesting of stock	12
Fair value of common stock at grant date \| $	$ 8,600
Restricted Stock [Member] \| Officers And Directors In Private Transaction [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares granted	1,100,000

SHARE CAPITAL (Summary of Option and Restricted Stock Granted to Employees) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2010	Dec. 31, 2012	Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of common stock at grant date		$ 8,600	$ 7,800
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted		2,944
Minimum exercise price	$ 6.32
Vesting period	4 years
2010 [Member] \| Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted		1,016
Maximum exercise price		$ 6.9
Vesting period		3 years
Fair value of common stock at grant date		$ 5,673
Expiration period		10 years
2010 [Member] \| Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted		428
Minimum exercise price		$ 6.32
Maximum exercise price		$ 9.66
Vesting period		4 years
Fair value of common stock at grant date		$ 2,147
Expiration period		10 years
2012 [Member] \| Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted		400
Vesting period		3 years
Fair value of common stock at grant date		$ 2,288
2012 [Member] \| Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted		1,100
Vesting period		4 years
Fair value of common stock at grant date		$ 6,292

SHARE CAPITAL (Fair Value Assumptions of Options Granted) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2010
SHARE CAPITAL [Abstract]
Dividend yield		0.00%
Expected volatility		75.00%
Risk free interest rate		3.23%
Expected life in years		8 years 9 months 18 days
Forfeiture rate	6.10%
Unrecognized share-based compensation expense	$ 7,000
Unrecognized compensation cost, recognition period	1 year 1 month 6 days
Fair value of common stock at grant date	$ 8,600	$ 7,800

SHARE CAPITAL (Options Granted to Employees) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cash proceeds from exercise of options	$ 1,230	$ 277	$ 501
Options And Restricted Stock Granted To Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance	6,141,030	6,367,979	5,366,729
Granted			1,444,000
Forfeited and Expired	25,858	44,856	13,441
Exercised	861,593	182,093	429,309
Ending Balance	5,253,579	6,141,030	6,367,979
Exercisable at end of year	4,258,441	4,647,834	4,267,850
Weighted Average Exercise Price, Beginning Balance	$ 3.563	$ 3.576	$ 2.476
Granted			7.076
Forfeited and Expired	4.372	6.207	3.551
Exercised	1.346	1.652	1.602
Exercisable at end of year	3.201	2.581	2.183
Weighted Average Exercise Price, Ending Balance	$ 3.923	$ 3.563	$ 3.576
Intrinsic value of options exercised	$ 4,800	$ 1,300	$ 3,100
Cash proceeds from exercise of options	$ 1,200

SHARE CAPITAL (Restricted Stock Granted to Employees) (Details)	12 Months Ended
	Dec. 31, 2012 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeited	3,208
Restricted Stock [Member] \| Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance
Granted	1,500,000
Forfeited	3,208
Balance	1,496,792
Exercisable at end of year	102,084

SHARE CAPITAL (Options Granted to Consultants, Directors and Other Service Providers) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cash proceeds from exercise of options	$ 1,230	$ 277	$ 501
Options Granted To Consultants Directors And Other Service Providers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance	1,238,692	1,438,692	1,438,692
Exercised	326,267	200,000
Ending Balance	912,425	1,238,692	1,438,692
Exercisable at end of year	912,425	1,235,567	1,421,734
Weighted Average Exercise Price, Beginning Balance	$ 5.385	$ 4.697	$ 4.697
Exercised	0.12	0.001
Weighted Average Exercise Price, Ending Balance	7.259	5.385	4.697
Exercisable at end of year	$ 7.259	$ 5.385	$ 4.653
Intrinsic value of options exercised	$ 2,300	$ 1,900	$ 0
Cash proceeds from exercise of options	$ 39

SHARE CAPITAL (Summary of Outstanding and Restricted Stocks) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2012 USD ($) $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Aggregate intrinsic value of the total outstanding and exercisable shares \| $	$ 19,700
Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options and restricted stock outstanding at end of year	1,496,792
Weighted average remaining contractual life	0 years
Number of options exercisable at end of year	102,084
Weighted average remaining contractual life, exercisable	0 years
Aggregate intrinsic value of the total outstanding and exercisable shares \| $	$ 12,400
Options And Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options and restricted stock outstanding at end of year	7,662,796
Number of options exercisable at end of year	5,272,950
0.001 [Member] \| Options And Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 0.001
Number of Options and restricted stock outstanding at end of year	719,207
Weighted average remaining contractual life	2 years 6 months 15 days
Number of options exercisable at end of year	719,207
Weighted average remaining contractual life, exercisable	2 years 6 months 15 days
0.120 [Member] \| Options And Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 0.12
Number of Options and restricted stock outstanding at end of year	447,850
Weighted average remaining contractual life	1 year 18 days
Number of options exercisable at end of year	447,850
Weighted average remaining contractual life, exercisable	1 year 18 days
0.399 [Member] \| Options And Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 0.399
Number of Options and restricted stock outstanding at end of year	23,087
Weighted average remaining contractual life	1 year 11 months 1 day
Number of options exercisable at end of year	23,087
Weighted average remaining contractual life, exercisable	1 year 11 months 1 day
0.972 [Member] \| Options And Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 0.972
Number of Options and restricted stock outstanding at end of year	996,353
Weighted average remaining contractual life	3 years 5 months 9 days
Number of options exercisable at end of year	996,353
Weighted average remaining contractual life, exercisable	3 years 5 months 9 days
2.350 [Member] \| Options And Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 2.35
Number of Options and restricted stock outstanding at end of year	40,000
Weighted average remaining contractual life	5 years 9 months 26 days
Number of options exercisable at end of year	40,000
Weighted average remaining contractual life, exercisable	5 years 9 months 26 days
2.650 [Member] \| Options And Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 2.65
Number of Options and restricted stock outstanding at end of year	402,882
Weighted average remaining contractual life	6 years 1 month 24 days
Number of options exercisable at end of year	396,744
Weighted average remaining contractual life, exercisable	6 years 1 month 24 days
3.020 [Member] \| Options And Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 3.02
Number of Options and restricted stock outstanding at end of year	50,000
Weighted average remaining contractual life	5 years 1 month 6 days
Number of options exercisable at end of year	50,000
Weighted average remaining contractual life, exercisable	5 years 1 month 6 days
5.000 [Member] \| Options And Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 5.0
Number of Options and restricted stock outstanding at end of year	1,708,000
Weighted average remaining contractual life	5 years 1 month 6 days
Number of options exercisable at end of year	1,708,000
Weighted average remaining contractual life, exercisable	5 years 1 month 6 days
6.810 [Member] \| Options And Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 6.81
Number of Options and restricted stock outstanding at end of year	160,000
Weighted average remaining contractual life	7 years 1 month 6 days
Number of options exercisable at end of year	110,000
Weighted average remaining contractual life, exercisable	7 years 1 month 6 days
6.900 [Member] \| Options And Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 6.9
Number of Options and restricted stock outstanding at end of year	1,003,083
Weighted average remaining contractual life	7 years 1 month 24 days
Number of options exercisable at end of year	168,083
Weighted average remaining contractual life, exercisable	7 years 1 month 24 days
7.550 [Member] \| Options And Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 7.55
Number of Options and restricted stock outstanding at end of year	160,000
Weighted average remaining contractual life	7 years 7 months 28 days
Number of options exercisable at end of year	90,000
Weighted average remaining contractual life, exercisable	7 years 7 months 28 days
9.660 [Member] \| Options And Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 9.66
Number of Options and restricted stock outstanding at end of year	68,000
Weighted average remaining contractual life	7 years 9 months 29 days
Number of options exercisable at end of year	34,000
Weighted average remaining contractual life, exercisable	7 years 9 months 29 days
16.700 [Member] \| Options And Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 16.7
Number of Options and restricted stock outstanding at end of year	387,542
Weighted average remaining contractual life	3 years 11 months 27 days
Number of options exercisable at end of year	387,542
Weighted average remaining contractual life, exercisable	3 years 11 months 27 days

SHARE CAPITAL (Share Based Compensation Expense Allocation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 7,751	$ 886	$ 1,282
Cost of Revenues [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	220
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	4,756	422	630
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 2,775	$ 464	$ 652

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References + Details

TAXES ON INCOME (Narrative) (Details) $ in Thousands	12 Months Ended
TAXES ON INCOME (Narrative) (Details) $ in Thousands	Dec. 31, 2012 USD ($)
Income Tax Disclosure [Line Items]
Withholding tax on the U.S. revenue source portion of the payments made to the Company for its share of Pfizer?s net profits	15.00%
Net operating loss carry forwards	$ 72,500
Tax rates expected to be in effect when deferred tax asset differences reverse	39%, 25% and 0%
Law for Amending the Israel Income Tax Ordinance - 2009, Tax year [Member]
Income Tax Disclosure [Line Items]
Statutory income tax rate	26.00%
Law for Amending the Israel Income Tax Ordinance, Tax Thereafter [Member]
Income Tax Disclosure [Line Items]
Statutory income tax rate	25.00%
Restricted Amount [Member]
Income Tax Disclosure [Line Items]
Net operating loss carry forwards	$ 13,800
Protalix Ltd. [Member]
Income Tax Disclosure [Line Items]
Additional gradual decrease in tax rate, 2012	23.00%
Additional gradual decrease in tax rate, 2013	22.00%
Additional gradual decrease in tax rate, 2014	21.00%
Additional gradual decrease in tax rate, 2015	20.00%
Additional gradual decrease in tax rate, 2016	18.00%
Additional gradual decrease in tax rate, thereafter	18.00%
Net operating loss carry forwards	$ 58,700
Protalix Ltd. [Member] \| Law for Amending the Israel Income Tax Ordinance, Tax Thereafter [Member]
Income Tax Disclosure [Line Items]
Statutory income tax rate	25.00%
Minimum [Member] \| Protalix Ltd. [Member]
Income Tax Disclosure [Line Items]
Statutory income tax rate	26.00%
Maximum [Member]
Income Tax Disclosure [Line Items]
Statutory income tax rate	39.00%
Maximum [Member] \| Protalix Ltd. [Member]
Income Tax Disclosure [Line Items]
Statutory income tax rate	25.00%

TAXES ON INCOME (Deferred Income Taxes) (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
TAXES ON INCOME [Abstract]
Research and development expenses	$ 6,003	$ 4,119
Property and equipment	(647)	(149)
Provision for vacation	363	305
Severance pay obligation	192	164
Deferred revenues	10,449	4,746
Net operating loss carry forwards	15,176	4,579
Valuation allowance	(31,536)	(13,764)
Deferred Tax Assets, Net of Valuation Allowance, Total

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.

+ References + Details

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.

+ References + Details

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from severance costs.

+ References + Details

TAXES ON INCOME (Open Tax Years) (Details)	12 Months Ended
TAXES ON INCOME (Open Tax Years) (Details)	Dec. 31, 2012
ISRAEL [Member] \| Minimum [Member]
Income Tax Contingency [Line Items]
Open tax year	2009
ISRAEL [Member] \| Maximum [Member]
Income Tax Contingency [Line Items]
Open tax year	2012
UNITED STATES [Member] \| Minimum [Member]
Income Tax Contingency [Line Items]
Open tax year	2009
UNITED STATES [Member] \| Maximum [Member]
Income Tax Contingency [Line Items]
Open tax year	2012
NETHERLANDS [Member] \| Minimum [Member]
Income Tax Contingency [Line Items]
Open tax year	2009
NETHERLANDS [Member] \| Maximum [Member]
Income Tax Contingency [Line Items]
Open tax year	2012

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Receivable, Other) (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Accounts, Notes, Loans and Financing Receivable [Line Items]
Prepaid expenses	$ 251	$ 235
Other receivables	3,686	3,837
Deferred Cost [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Other receivables	89	1,558
Institutions [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Other receivables	542	375
State Of Israel [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Other receivables	2,400	1,296
Restricted Deposit [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Other receivables	298	208
Sundry [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Other receivables	$ 106	$ 165

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals, Other) (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Accounts Payable And Accruals [Line Items]
Payroll and related expenses	$ 1,748	$ 1,108
Provision for vacation	1,453	1,221
Accrued expenses	2,032	2,327
Royalties payable	1,560	89
Accounts payable and accruals, other	11,051	7,540
Collaboration Operation Current Portion [Member]
Accounts Payable And Accruals [Line Items]
Accounts payable and accruals, other	3,122	1,322
Property And Equipment Suppliers [Member]
Accounts Payable And Accruals [Line Items]
Accounts payable and accruals, other	$ 1,136	$ 1,473

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Revenues) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Supplemental Information Revenue [Line Items]
Revenues	$ 34,870	$ 8,386	$ 6,642
Deferred Revenue From License And Supply Agreement With Pzifer [Member]
Supplemental Information Revenue [Line Items]
Revenues	4,563	4,563	4,563
Milestone Payments [Member]
Supplemental Information Revenue [Line Items]
Revenues	25,000
Revenues from selling products [Member]
Supplemental Information Revenue [Line Items]
Revenues	$ 5,307	$ 3,823	$ 2,079

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Management And Consulting Fees To Chairman Of Board [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction			$ 6
Compensation To The Non -executiveDirectors [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction	$ 375	$ 215	$ 215

SUBSEQUENT EVENTS (Details) - USD ($) $ in Thousands	2 Months Ended	12 Months Ended
SUBSEQUENT EVENTS (Details) - USD ($) $ in Thousands	Feb. 28, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Subsequent Event [Line Items]
Cash proceeds from exercise of options		$ 1,230	$ 277	$ 501
Option Exercise [Member] \| Certain Employee [Member]
Subsequent Event [Line Items]
Common Stock issued in connection with exercise of options	8,000
Cash proceeds from exercise of options	$ 19

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 19
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph i
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details